AU2014284212B2 - Methods for treatment of ovarian cancer - Google Patents

Methods for treatment of ovarian cancer Download PDF

Info

Publication number
AU2014284212B2
AU2014284212B2 AU2014284212A AU2014284212A AU2014284212B2 AU 2014284212 B2 AU2014284212 B2 AU 2014284212B2 AU 2014284212 A AU2014284212 A AU 2014284212A AU 2014284212 A AU2014284212 A AU 2014284212A AU 2014284212 B2 AU2014284212 B2 AU 2014284212B2
Authority
AU
Australia
Prior art keywords
antibody
seq
subject
level
fra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014284212A
Other languages
English (en)
Other versions
AU2014284212A1 (en
Inventor
Daniel John O'shannessy
Charles Schweizer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AU2014284212A1 publication Critical patent/AU2014284212A1/en
Assigned to EISAI, INC. reassignment EISAI, INC. Request for Assignment Assignors: MORPHOTEK, INC.
Application granted granted Critical
Publication of AU2014284212B2 publication Critical patent/AU2014284212B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014284212A 2013-06-20 2014-06-20 Methods for treatment of ovarian cancer Ceased AU2014284212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837543P 2013-06-20 2013-06-20
US61/837,543 2013-06-20
PCT/US2014/043402 WO2014205342A2 (en) 2013-06-20 2014-06-20 Methods for treatment of ovarian cancer

Publications (2)

Publication Number Publication Date
AU2014284212A1 AU2014284212A1 (en) 2015-12-17
AU2014284212B2 true AU2014284212B2 (en) 2019-09-12

Family

ID=52105530

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014284212A Ceased AU2014284212B2 (en) 2013-06-20 2014-06-20 Methods for treatment of ovarian cancer

Country Status (8)

Country Link
US (2) US20160311921A1 (https=)
EP (1) EP3011013A4 (https=)
JP (1) JP6383787B2 (https=)
AU (1) AU2014284212B2 (https=)
BR (1) BR112015031950A2 (https=)
CA (1) CA2914237A1 (https=)
MX (1) MX2015017950A (https=)
WO (1) WO2014205342A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
AU2016323968B2 (en) * 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
WO2019099374A2 (en) * 2017-11-14 2019-05-23 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
US20230074385A1 (en) * 2019-12-23 2023-03-09 Eisai R&D Management Co., Ltd. Method for producing eribulin-based antibody-drug conjugate
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120207771A1 (en) * 2010-11-05 2012-08-16 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
US6351666B1 (en) 1998-02-27 2002-02-26 Biofield Corp. Method and apparatus for sensing and processing biopotentials
JP3952599B2 (ja) 1998-07-16 2007-08-01 松下電器産業株式会社 映像表示装置および映像表示方法
WO2000004711A1 (en) 1998-07-16 2000-01-27 Imageid Ltd. Image identification and delivery system
US6694090B1 (en) 1998-07-20 2004-02-17 Thomson Licensing S.A. Method and apparatus for dynamically overriding a ratings limit during playback of a digital program
DE69900584T3 (de) 1998-07-21 2009-05-20 Nxp B.V. System zur übertragung von daten von einem datenträger nach einer station mittels eines oder zum mindest eines anderen hilfsträgersignals
IT1303624B1 (it) 1998-07-22 2000-11-15 Techint Spa Dispositivo per elettrodeposizione a cella circonferenziale a flussidifferenziati.
DE19833226C1 (de) 1998-07-23 2000-04-20 Steuler Industriewerke Gmbh Niederschlagsrohrbündel für Naßelektrofilter
DE19833340A1 (de) 1998-07-24 2000-02-10 Karlsruhe Forschzent Wurmförmiger Arbeitsmechanismus
AU5311599A (en) 1998-07-24 2000-02-14 Ce Resources Pte Ltd Array electrophoretic apparatus
CN1106227C (zh) 1998-07-24 2003-04-23 宝洁公司 具有带有改进的汲取管的抽吸分取器的内置袋型包装物
US6386399B1 (en) 1998-07-24 2002-05-14 Yoshino Kogyosho Co., Ltd. Container with manual pump
IT1301872B1 (it) 1998-07-24 2000-07-07 Abb Adda S P A Dispositivo di comando e controllo di interruttori di alta e mediatensione
WO2003094929A2 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
US8986650B2 (en) * 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
AU2007335744A1 (en) * 2006-12-20 2008-06-26 Alberto A. Gabizon Method for administration of pegylated liposomal doxorubicin
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
PL2731972T3 (pl) 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania
HUE049693T2 (hu) * 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120207771A1 (en) * 2010-11-05 2012-08-16 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG DEBORAH K ET AL, "Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.", GYNECOLOGIC ONCOLOGY, (2013-06), vol. 129, no. 3, ISSN 1095-6859, pages 452 - 458 *
O'SHANNESSY, D.J. ET AL, "Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.", J Ovar Res, (2013-04-17), vol. 6, no. 1 *

Also Published As

Publication number Publication date
WO2014205342A4 (en) 2015-06-04
WO2014205342A2 (en) 2014-12-24
MX2015017950A (es) 2016-05-10
EP3011013A4 (en) 2017-03-15
BR112015031950A2 (pt) 2017-07-25
EP3011013A2 (en) 2016-04-27
AU2014284212A1 (en) 2015-12-17
JP2016529484A (ja) 2016-09-23
CA2914237A1 (en) 2014-12-24
US20160311921A1 (en) 2016-10-27
WO2014205342A3 (en) 2015-04-23
US20190202930A1 (en) 2019-07-04
JP6383787B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
US20190202930A1 (en) Methods for treatment of ovarian cancer
EP3283886B1 (en) Methods for treating lung cancer
US12287337B2 (en) Autoantibody biomarkers of ovarian cancer
US20140341893A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US20170166654A1 (en) Protein biomarker and uses thereof
US10221240B2 (en) Methods for treatment of gastric cancer
KR20180013878A (ko) 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
JP2022512590A (ja) ソラフェニブ化合物を含む療法のためのバイオマーカー
HK1198063A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
NZ624444B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EISAI, INC.

Free format text: FORMER APPLICANT(S): MORPHOTEK, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired